CLEC3A

Summary

CLEC3A (C-type lectin domain family 3 member A, HGNC:2052) is a protein-coding gene on chromosome 16q23.1, encoding C-type lectin domain family 3 member A (O75596). Promotes cell adhesion to laminin-332 and fibronectin.

Predicted to enable carbohydrate binding activity. Predicted to be involved in ossification. Predicted to be located in extracellular region. Predicted to be active in extracellular space.

Source: NCBI Gene 10143 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 36 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_005752

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2052
Approved symbol	CLEC3A
Name	C-type lectin domain family 3 member A
Location	16q23.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000166509
Ensembl biotype	protein_coding
OMIM	613588
Entrez	10143

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000299642, ENST00000565808, ENST00000567430, ENST00000651443

RefSeq mRNA: 1 — MANE Select: NM_005752 NM_005752

CCDS: CCDS10927

Canonical transcript exons

ENST00000299642 — 3 exons

Exon	Start	End
ENSE00001103708	78028107	78028190
ENSE00001103712	78030447	78032101
ENSE00003895828	78022548	78022741

Expression profiles

Bgee: expression breadth broad, 79 present calls, max score 91.96.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0963 / max 34.7786, expressed in 22 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155078	0.0963	22

Top tissues by expression

212 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibia	UBERON:0000979	91.96	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.02	gold quality
pancreatic ductal cell	CL:0002079	73.19	silver quality
tibialis anterior	UBERON:0001385	67.73	silver quality
ileal mucosa	UBERON:0000331	66.65	silver quality
gall bladder	UBERON:0002110	65.34	gold quality
cardiac muscle of right atrium	UBERON:0003379	65.02	gold quality
left ventricle myocardium	UBERON:0006566	64.63	gold quality
deltoid	UBERON:0001476	60.17	gold quality
urinary bladder	UBERON:0001255	58.03	gold quality
right coronary artery	UBERON:0001625	57.57	gold quality
epithelial cell of pancreas	CL:0000083	56.25	gold quality
myocardium	UBERON:0002349	55.91	gold quality
quadriceps femoris	UBERON:0001377	54.87	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
vastus lateralis	UBERON:0001379	53.22	gold quality
cartilage tissue	UBERON:0002418	51.69	gold quality
calcaneal tendon	UBERON:0003701	51.59	gold quality
left coronary artery	UBERON:0001626	51.57	gold quality
coronary artery	UBERON:0001621	51.41	gold quality
ascending aorta	UBERON:0001496	50.90	gold quality
thoracic aorta	UBERON:0001515	49.87	gold quality
mucosa of stomach	UBERON:0001199	49.21	gold quality
descending thoracic aorta	UBERON:0002345	49.19	gold quality
trachea	UBERON:0003126	49.03	gold quality
nasal cavity epithelium	UBERON:0005384	48.29	gold quality
aorta	UBERON:0000947	48.27	gold quality
tendon	UBERON:0000043	48.06	gold quality
fundus of stomach	UBERON:0001160	47.50	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93
E-CURD-7	no	73.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting CLEC3A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-570-3P	99.96	72.41	4910
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-5004-3P	99.54	68.27	1371
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-103A-1-5P	99.39	67.78	1545

Literature-anchored findings (GeneRIF, showing 4)

• CLEC3A binds to heparan sulfate proteoglycans on cell surface, leading to the enhancement of cell adhesion to integrin ligands on ECM; cleavage of CLEC3A by MMP-7 weakens the stable adhesion of tumor cells to the matrix (PMID:19173304)
• we demonstrated that the recurrence potential in PNETs is characterized by the upregulation of genes related to ECM organization and cell adhesion. This study identified three genes-CLEC3, MMP7, and LCN2-that contribute to the prediction of postoperative recurrence of PNETs in clinical practice. (PMID:31129920)
• Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1alpha signaling pathway. (PMID:32319617)
• C-type lectin domain-containing protein CLEC3A regulates proliferation, regeneration and maintenance of nucleus pulposus cells. (PMID:35864364)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	CLEC3A	ENSDARG00000110756
mus_musculus	Clec3a	ENSMUSG00000008874
rattus_norvegicus	Clec3a	ENSRNOG00000070954

Paralogs (2): CLEC11A (ENSG00000105472), CLEC3B (ENSG00000163815)

Protein

Protein identifiers

C-type lectin domain family 3 member A — O75596 (reviewed: O75596)

Alternative names: C-type lectin superfamily member 1, Cartilage-derived C-type lectin

All UniProt accessions (3): O75596, H3BTK1, J3KNC9

UniProt curated annotations — full annotation on UniProt →

Function. Promotes cell adhesion to laminin-332 and fibronectin.

Subcellular location. Secreted.

Tissue specificity. Restricted to cartilage and breast. Also expressed in breast cancers.

RefSeq proteins (1): NP_005743* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR051663	CLec_Tetranectin-domain	Family

Pfam: PF00059

UniProt features (7 total): disulfide bond 3, signal peptide 1, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75596-F1	92.50	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 68–78, 95–191, 167–183

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 49 (showing top): GOBP_SKELETAL_SYSTEM_DEVELOPMENT, MODULE_205, NF1_Q6_01, TGCTGAY_UNKNOWN, MODULE_410, GOBP_OSSIFICATION, MODULE_207, MODULE_95, TCTGATC_MIR383, AR_Q6, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, MODULE_163, chr16q23, MIR1468_3P, MIR548P

GO Biological Process (2): skeletal system development (GO:0001501), ossification (GO:0001503)

GO Molecular Function (1): carbohydrate binding (GO:0030246)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
system development	1
multicellular organismal process	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLEC3A	MMP7	P09237	673
CLEC3A	LAMA1	P25391	669
CLEC3A	VAT1L	Q9HCJ6	536
CLEC3A	CLEC1B	Q9P126	531
CLEC3A	CLEC2B	Q92478	513
CLEC3A	CHRDL2	Q6WN34	485
CLEC3A	CYTL1	Q9NRR1	481
CLEC3A	WWOX	Q9NZC7	450
CLEC3A	CDYL2	Q8N8U2	443
CLEC3A	SYF2	O95926	441
CLEC3A	FN1	P02751	437
CLEC3A	CNMD	O75829	429
CLEC3A	TAF1D	Q9H5J8	398
CLEC3A	CILP	O75339	385
CLEC3A	PRELP	P51888	380

IntAct

11 interactions, top by confidence:

A	B	Type	Score
HIKESHI	CLEC3A	psi-mi:“MI:0914”(association)	0.530
CLEC3A	ZZEF1	psi-mi:“MI:0914”(association)	0.530
CLEC3A	ZNF593	psi-mi:“MI:0914”(association)	0.350
TOR1A	CLEC3A	psi-mi:“MI:0914”(association)	0.350
RCAN1	CLEC3A	psi-mi:“MI:0914”(association)	0.350
FAAP20	FANCG	psi-mi:“MI:0914”(association)	0.350
CLEC3A	MACROH2A1	psi-mi:“MI:0914”(association)	0.350
CLEC3A	TRIP4	psi-mi:“MI:0914”(association)	0.350

BioGRID (79): RNASEH1 (Affinity Capture-MS), PHF10 (Affinity Capture-MS), YY1AP1 (Affinity Capture-MS), ZNF430 (Affinity Capture-MS), CACTIN (Affinity Capture-MS), RBM23 (Affinity Capture-MS), KBTBD7 (Affinity Capture-MS), CTNNBL1 (Affinity Capture-MS), LSM14B (Affinity Capture-MS), C1QBP (Affinity Capture-MS), CLEC3A (Affinity Capture-MS), RBM27 (Affinity Capture-MS), KBTBD6 (Affinity Capture-MS), ZNF638 (Affinity Capture-MS), CLEC3A (Affinity Capture-MS)

ESM2 similar proteins: A3FM55, B4XSY7, B4XSY8, B4XSZ1, C0HKZ6, D1MGU0, F1QVU0, O09037, O60449, O75596, O89103, O93426, P06681, P14371, P18292, P19221, P21180, P23132, P25031, P28824, P30836, P35230, P35231, P49259, P49260, P81017, P81112, P98131, Q08731, Q09GJ8, Q09GK0, Q13018, Q28008, Q3SYW2, Q4PRD2, Q568T5, Q5R880, Q60767, Q62028, Q6T7B5

Diamond homologs: O02659, O75596, P06734, P06908, P07307, P08290, P08427, P08661, P11226, P12842, P19999, P20693, P23805, P24721, P34927, P35242, P35247, P35248, P39039, P41317, P49300, P49301, P49874, P50403, P50404, P82596, Q17QH6, Q1PBC5, Q28008, Q2KIS7, Q2LK54, Q2LK94, Q2LK95, Q5M8X6, Q5MIZ0, Q5U3G1, Q5U9S1, Q66KU1, Q66S37, Q66S41

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	26
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
4279196	GRCh37/hg19 16q23.1(chr16:77960665-78530885)x1	Pathogenic
624464	GRCh37/hg19 16q23.1(chr16:77981957-79037091)x1	Likely pathogenic

SpliceAI

401 predictions. Top by Δscore:

Variant	Effect	Δscore
16:78022716:G:GT	donor_gain	1.0000
16:78030445:A:AG	acceptor_gain	1.0000
16:78030446:G:GG	acceptor_gain	1.0000
16:78030446:GTCT:G	acceptor_gain	1.0000
16:78022738:AGAG:A	donor_gain	0.9900
16:78022739:GAG:G	donor_gain	0.9900
16:78022739:GAGG:G	donor_gain	0.9900
16:78022740:AG:A	donor_loss	0.9900
16:78022741:GGTAA:G	donor_loss	0.9900
16:78022742:G:GA	donor_loss	0.9900
16:78022743:T:A	donor_loss	0.9900
16:78030446:GT:G	acceptor_gain	0.9900
16:78030446:GTC:G	acceptor_gain	0.9900
16:78028186:GACAG:G	donor_gain	0.9800
16:78028190:GGTA:G	donor_loss	0.9800
16:78028191:GTAAG:G	donor_loss	0.9800
16:78028192:T:A	donor_loss	0.9800
16:78030430:A:AG	acceptor_gain	0.9800
16:78028094:A:G	acceptor_gain	0.9700
16:78030431:C:G	acceptor_gain	0.9700
16:78030442:CACA:C	acceptor_loss	0.9700
16:78030444:CA:C	acceptor_loss	0.9700
16:78030445:A:AT	acceptor_loss	0.9700
16:78022734:A:AG	donor_gain	0.9600
16:78022735:G:GG	donor_gain	0.9600
16:78022880:GGGAT:G	donor_gain	0.9600
16:78028105:A:AG	acceptor_gain	0.9600
16:78028106:G:GG	acceptor_gain	0.9600
16:78022736:TGAG:T	donor_gain	0.9500
16:78028104:CAGAC:C	acceptor_loss	0.9500

AlphaMissense

1300 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:78030531:G:A	C95Y	0.998
16:78030532:C:G	C95W	0.998
16:78030709:G:C	W154C	0.998
16:78030709:G:T	W154C	0.998
16:78030479:T:A	C78S	0.997
16:78030480:G:C	C78S	0.997
16:78030518:G:C	A91P	0.997
16:78030530:T:A	C95S	0.997
16:78030531:G:C	C95S	0.997
16:78030634:G:C	W129C	0.996
16:78030634:G:T	W129C	0.996
16:78030779:T:A	W178R	0.996
16:78030779:T:C	W178R	0.996
16:78030818:T:A	C191S	0.996
16:78030819:G:A	C191Y	0.996
16:78030819:G:C	C191S	0.996
16:78030449:T:A	C68S	0.995
16:78030450:G:C	C68S	0.995
16:78030479:T:C	C78R	0.995
16:78030530:T:C	C95R	0.995
16:78030746:T:A	C167S	0.995
16:78030747:G:C	C167S	0.995
16:78030748:T:G	C167W	0.995
16:78030481:C:G	C78W	0.994
16:78030531:G:T	C95F	0.994
16:78030632:T:A	W129R	0.994
16:78030632:T:C	W129R	0.994
16:78030747:G:A	C167Y	0.994
16:78030449:T:C	C68R	0.993
16:78030451:T:G	C68W	0.993

dbSNP variants (sampled 300 via entrez): RS1000055292 (16:78025309 C>G), RS1000415948 (16:78022176 A>G), RS1000488111 (16:78022317 A>G,T), RS1000716427 (16:78027396 G>A), RS1000751192 (16:78023065 G>C), RS1000784392 (16:78026519 A>C,G), RS1000807323 (16:78023128 G>C), RS1000826529 (16:78023201 G>A,C,T), RS1000879497 (16:78023012 G>A,C), RS1001142481 (16:78022295 C>T), RS1001370340 (16:78025853 C>A), RS1001490737 (16:78031133 T>A), RS1001827637 (16:78032034 A>G), RS1001867649 (16:78028654 T>G), RS1002339908 (16:78032200 TG>T)

Disease associations

OMIM: gene MIM:613588 | disease phenotypes: MIM:616211

GenCC curated gene-disease

Mondo (2): developmental and epileptic encephalopathy, 28 (MONDO:0014533), autism spectrum disorder (MONDO:0005258)

Orphanet (2): Non-specific early-onset epileptic encephalopathy (Orphanet:442835), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002307_5	Systolic blood pressure (alcohol consumption interaction)	9.000000e-07
GCST003209_15	Colorectal or endometrial cancer	1.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004329	alcohol drinking
EFO:0006335	systolic blood pressure
EFO:0004230	endometrial neoplasm

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
tungsten carbide	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Cadmium	decreases expression	1
Carbamazepine	affects expression	1
Cobalt	affects binding, decreases expression	1
Aflatoxin B1	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder